TICKERNOMICS Sign up
Last Update: 2024-12-27 15:25:25
CAPRICOR THERAPEUTICS INC. ( CAPR ) https://www.capricor.com
14.08USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
CAPR
184.73%
SPY
32.66%
CAPR
374.07%
SPY
108.59%
CAPR
1113.79%
SPY
302.52%
-62.45%
CAPR
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
465.91
-16252.04
0.69
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-13.66
20.06
6.82
-8138.84
0.00
349.76
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-575.24
100000.00
-346.72
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
21.6896
-42690.06
-177.41
4.72
Other Earnings and Cash Flow Stats:
CAPRICOR THERAPEUTICS INC. ( CAPR ) Net Income TTM ($MM) is -34.11
CAPRICOR THERAPEUTICS INC. ( CAPR ) Operating Income TTM ($MM) is -35.93
CAPRICOR THERAPEUTICS INC. ( CAPR ) Owners' Earnings Annual ($MM) is -27.47
CAPRICOR THERAPEUTICS INC. ( CAPR ) Current Price to Owners' Earnings ratio is -4.65
CAPRICOR THERAPEUTICS INC. ( CAPR ) EBITDA TTM ($MM) is -34.57
CAPRICOR THERAPEUTICS INC. ( CAPR ) EBITDA Margin is -346.72%
Capital Allocation:
CAPRICOR THERAPEUTICS INC. ( CAPR ) has paid 0.00 dividends per share and bought back -7.272387 million shares in the past 12 months
CAPRICOR THERAPEUTICS INC. ( CAPR ) has reduced its debt by 0.7647 million USD in the last 12 months
Capital Structure:
CAPRICOR THERAPEUTICS INC. ( CAPR ) Interest-bearing Debt ($MM) as of last quarter is 1
CAPRICOR THERAPEUTICS INC. ( CAPR ) Annual Working Capital Investments ($MM) are -23162
CAPRICOR THERAPEUTICS INC. ( CAPR ) Book Value ($MM) as of last quarter is 68
CAPRICOR THERAPEUTICS INC. ( CAPR ) Debt/Capital as of last quarter is 2%
Other Balance Sheet Stats:
CAPRICOR THERAPEUTICS INC. ( CAPR ) has 68 million in cash on hand as of last quarter
CAPRICOR THERAPEUTICS INC. ( CAPR ) has 20 million of liabilities due within 12 months, and long term debt 0 as of last quarter
CAPRICOR THERAPEUTICS INC. ( CAPR ) has 33 common shares outstanding as of last quarter
CAPRICOR THERAPEUTICS INC. ( CAPR ) has 0 million USD of preferred stock value
Academic Scores:
CAPRICOR THERAPEUTICS INC. ( CAPR ) Altman Z-Score is 7.71 as of last quarter
CAPRICOR THERAPEUTICS INC. ( CAPR ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
CAPRICOR THERAPEUTICS INC. ( CAPR ) largest shareholder is owning shares at 0.00 ($MM) value
Nippon Shinyaku Co Ltd(an insider) Bought 2798507 shares of CAPRICOR THERAPEUTICS INC. ( CAPR ) for the amount of $14999997.52 on 2024-09-20
16.73% of CAPRICOR THERAPEUTICS INC. ( CAPR ) is held by insiders, and 24.56% is held by institutions
CAPRICOR THERAPEUTICS INC. ( CAPR ) went public on 2007-02-13
Other CAPRICOR THERAPEUTICS INC. ( CAPR ) financial metrics:
FCF:-25889.75
Unlevered Free Cash Flow:-36.72
EPS:-1.52
Operating Margin:-575.24
Gross Profit Margin:100000.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-73.58
Beta:4.72
Buffet's Owners Earnings:-27.47
Price to Owner's Earnings:-4.65
About CAPRICOR THERAPEUTICS INC. ( CAPR ) :
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome platform technology which generated two vaccine candidates, such as STX-S and STX-N, induced an immune response against two SARS-CoV-2 proteins, spike, and nucleocapsid, as well as developing vaccines and therapeutics for infectious and monogenic diseases, and other potential indications. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.